Next 10 |
home / stock / vph:cc / vph:cc news
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million ...
VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES Canada NewsWire Record Q2-24 revenues of $14.1 million , up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million fo...
Troilus Gold Corp. (TLG:CA) is expected to report for Q3 2024 NeutriSci International Inc. (NU:CA) is expected to report for Q1 2024 BluMetric Environmental Inc. (BLM:CA) is expected to report for Q2 2024 Memex Inc. (OEE:CA) is expected to report for Q2 2024 Blackline Safety Corp....
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...
VALEO PHARMA TO HOST SECOND QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , June 4, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, annou...
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE Canada NewsWire MONTREAL , April 9, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB...
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS Canada NewsWire MONTREAL , March 22, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, t...
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS Canada NewsWire Q1-24 revenues of $13.5 million , up 3% over Q1-23 Q1-24 adjusted EBITDA loss of $2.1 million compared to $2.2 million for Q1-23, down 6% Total Enerzair and Atectura prescriptions for...
Nexus Industrial REIT (NXR.UN:CA) is expected to report $0.19 for Q4 2023 Flagship Communities Real Estate Investment Trust (MHC.U:CA) is expected to report $0.4 for Q4 2023 Bridgemarq Real Estate Services Inc. Restricted Voting Shares (BRE:CA) is expected to report for quarter end 2023-1...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million ...
VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES Canada NewsWire Record Q2-24 revenues of $14.1 million , up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million fo...